Vol.:(0123456789)
Archives of Toxicology (2025) 99:2669–2681 
https://doi.org/10.1007/s00204-025-04008-0
SHORT COMMUNICATION
A clinical chemical atlas of xenobiotic toxicity for the Sprague–Dawley 
rat
Janonna Kadyrov1,2 · Samuele Sala1,2 · Lucy Grigoroff1,2 · Novia Minaee1,2 · Reika Masuda1,2 · Samantha Lodge1,2 · 
Timothy M. Ebbels3 · Michael D. Reily4 · Donald Robertson4 · Lois Lehman‑McKeeman5 · John Shockcor6 · 
Bruce D. Car5 · Glenn H. Cantor5 · John C. Lindon7 · Jeremy K. Nicholson1,2,8 · Elaine Holmes1,2,7 · Julien Wist1,2,8,9 
Received: 3 December 2024 / Accepted: 24 February 2025 / Published online: 6 May 2025 
© The Author(s) 2025
Abstract
The Consortium for Metabonomic Toxicology (COMET) studies was designed to model metabolic responses to organ- and 
mechanism-specific toxins to predict acute drug toxicity in rats. A range of clinical chemical parameters were measured in 
7-day toxicology studies for 86 toxins eliciting a range of organ- and mechanism-specific effects. Additionally, 21 surgical or 
physiological stressors were evaluated to identify physiological or metabolic responses that might confound the interpreta-
tion of observed toxicity profiles. From these studies on a total of 3473 rats measured at six pharmaceutical companies, we 
provide a set of 12 serum and 5 urine physical and clinical chemistry parameters. Samples were collected at 24 h, 48 h and 
168 h post-dose for each animal and are presented as a downloadable database file. We also summarise the main observa-
tions based on the group response at the level of the individual toxin. We demonstrate that correlations between parameters, 
such as serum bilirubin and aspartate aminotransferase (AST), provide a more nuanced profile of organ-specific toxicity than 
consideration of individual parameters alone. In addition, we highlight the variability in the measured parameters across the 
dataset attributable to inter-laboratory differences, and the heterogeneity of metabolic responses to particular compounds or 
differences in temporal patterns of response. This clinical chemistry atlas of toxicity serves as a valuable reference tool for 
evaluating the potential toxicity of novel drug candidates.
Keywords Clinical chemistry · Toxicity · COMET project · Biofluid · Rats · Sprague–Dawley
 * Jeremy K. Nicholson 
 Jeremy.Nicholson@murdoch.edu.au; 
j.nicholson@imperial.ac.uk
 * Elaine Holmes 
 Elaine.Holmes@murdoch.edu.au
 * Julien Wist 
 Julien.wist@murdoch.edu.au; 
julien.wist@correounivalle.edu.co
1 Australian National Phenome Centre, Health Futures 
Institute, Murdoch University, Perth, WA, Australia
2 Centre for Computational and Systems Medicine, Health 
Futures Institute, Murdoch University, Perth, WA, Australia
3 Department of Metabolism, Digestion and Reproduction, 
Faculty of Medicine, Hammersmith Campus, Imperial 
College London, London W12 0NN, UK
4 Formerly Pfizer Global R&D, Ann Arbor, MI, USA
5 Formerly Bristol-Myers-Squibb Company, Princeton, NJ, 
USA
6 Formerly Drug Metabolism and Pharmacokinetics Section, 
Dupont Pharmaceuticals Company, Stine-Haskell Research 
Center, Newark, Delaware, USA
7 Department of Metabolism, Digestion and Reproduction, 
Faculty of Medicine, Imperial College London, London, UK
8 Institute of Global Health Innovation, Faculty of Medicine, 
Imperial College London, London SW7 2AZ, UK
9 Chemistry Department, Universidad del Valle, 76001 Cali, 
Colombia
2670 Archives of Toxicology (2025) 99:2669–2681
Introduction
Drug safety issues are a major cause (ca 35–40%) of attri-
tion of drug candidates (Tosca et al. 2021), with hepato-
toxicity, cardiotoxicity and nephrotoxicity accounting for 
the majority of withdrawals from the market (Wilke et al. 
2007). As part of the development of a new drug, a rigor -
ous, multi-stage pipeline for safety testing is implemented 
involving a series of in vitro (cytotoxicity, genotoxicity, 
drug–drug interactions) and in vivo (acute, sub-acute, 
chronic, carcinogenicity) evaluations to ensure that new 
drug candidates are safe for human use (Walker et al. 2020; 
Stark and Steger-Hartmann 2015 ). Several tools have been 
adopted within the pharmaceutical industry for screening 
drug candidates with a view to minimising attrition and 
hence cost by early elimination of products associated with 
toxicity or adverse reactions. In silico screenings have 
contributed increasingly to reducing drug induced toxic-
ity over the last few years (Amorim et al. 2024; Tran et al. 
2023). The most common computational approaches are 
those based on quantitative structure–activity relationships 
which are rooted in a range of different machine learn-
ing approaches (Tosca et al. 2021). Such methods can be 
trained or validated on data from in vitro or in vivo studies 
and used as early screening tools.
Prior to clinical (human) testing, in vivo toxicity testing 
involves preclinical (non-human) evaluation, with one of 
the most common paradigms consisting of a 7-day acute 
toxicity study in rodents (typically mouse or rat). The rat 
has been a popular choice for acute toxicity evaluation 
based on the size, ease of handling, short breeding cycle 
and similarity to humans in response to multiple types of 
compounds (Smith et al. 2019). In addition, the historical 
use of rodent models in toxicity testing has resulted in 
the accumulation of vast amounts of data on clinical and 
physiological parameters. Although the pharmaceutical 
industry has increasingly come to rely on postgenomic 
technologies in the evaluation of drug safety, the 7-day 
toxicity study with conventional clinical chemistry tests 
and histological assessment remains a key feature of the 
safety evaluation for new drug candidates.
In 1999, six pharmaceutical companies (namely, Bris-
tol Myers Squibb, Eli Lilly and Co., Hoffman–La Roche, 
NovoNordisk, Pfizer Incorporated, and The Pharmacia 
Corporation) and an academic partner (Imperial Col-
lege London) came together to explore the formation of 
a consortium with the aim of generating a comprehen-
sive toxicological database of NMR spectra anchored 
with conventional clinical chemistry and histopathology 
measurements to construct an expert system for predic-
tion of organ- or mechanism-specific toxicity (Lindon 
et al. 2003). NMR-based metabolic phenotyping is an 
approach that can identify novel biomarkers of liver and 
kidney toxicity before any clinical effects occur, which 
would be invaluable in identifying hepatotoxicity- and 
nephrotoxicity-inducing drugs early on and preventing 
such drugs progressing through clinical trials and to mar -
ket (Nicholson et al. 1989; Sanins et al. 1992; Nichol-
son et al. 2002; Olesti et al. 2021; Shockcor and Holmes 
2002; Robertson 2005; Araújo et al. 2021; Robertson et al. 
2011). Over a 3-year period starting in 2001, the consor -
tium sought to study 86 acute toxins and 21 induced physi-
ological conditions that confound the interpretation of tox-
icity data in the Sprague–Dawley rat, building databases 
and predictive models to better understand and mitigate 
drug toxicity. The resulting databases and models were 
used internally by several of the pharmaceutical company 
partners with the aim of improving the early identification 
of therapeutic candidates with adverse effects. Multiple 
publications reporting new understanding of toxic mecha-
nisms (Lindon et al. 2005, 2003; Ebbels et al. 2007; Cantor 
et al. 2013; Bohus et al. 2008) and physiological responses 
associated with toxic side effects, for example weight loss 
(Veselkov et al. 2010) or liver regeneration (Bollard et al. 
2010), were generated.
Although the main aim of the consortium was to gener -
ate information-dense metabolic profiles of each of the tox-
ins using proton nuclear magnetic resonance spectroscopy 
(1H NMR) (Lindon et al. 2005), modelling the changes in the 
metabolic profiles required information from conventional 
toxicological endpoints such as histopathological assessment 
and clinical chemistry assays. Since this is one of the larg-
est collections of rodent toxicology studies ever conducted 
under identical protocols across multiple laboratories, we are 
now making these data publicly available to provide reference 
ranges for the various data modalities. Here, we report the clin-
ical chemistry medians and ranges for serum calcium, sodium, 
potassium, phosphate, glucose, albumin, total protein, total 
bilirubin, urea nitrogen, creatinine, alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST), and for urinary 
volume, pH, osmolality, glucose and protein for the 107 treat-
ments and for matched control animals across multiple time 
points. We provide a downloadable SQL database containing 
the curated clinical chemistry parameters at the individual ani-
mal level. Thus, this paper provides a clinical chemical atlas 
of liver, kidney, testicular and pancreatic toxicity based on 
standard laboratory parameters.
Methods
Experimental design
The study design for the 7-day toxicology experi-
ments used in the COMET project is standard in most 
2671Archives of Toxicology (2025) 99:2669–2681 
pharmaceutical companies and has been reported else-
where but is described here briefly and summarised in 
a schematic diagram (Fig.  1). All animal studies were 
conducted in accordance with the current guidelines for 
animal welfare (Guide for the Care and Use of Laboratory 
Animals, 1996) and the procedures used were reviewed 
and approved by the Institutional Animal Care and Use 
Committee in each company. Studies were carried out 
within the laboratories of each of the companies (Bris-
tol Myers Squibb, Eli Lilly and Co., Hoffman–La Roche, 
NovoNordisk, Pfizer Incorporated, and The Pharmacia 
Corporation), who have been randomly assigned a let-
ter from A to F for the purpose of reporting the data. A 
total of 86 toxins that induce toxic effects to the liver, 
kidney, pancreas and/or testes were selected and adminis-
tered in an appropriate dose vehicle, predominantly saline 
or corn oil, either orally or via an intraperitoneal injec-
tion as defined in Table  1. For each compound studied, 
30 rats (8- to 10-week-old male Sprague–Dawley from 
Charles River Laboratories) were allocated randomly 
into a control group, a low-dose group and a high-dose 
group with dosing levels being based on the literature or 
earlier dose-range finding studies to generate a threshold 
and a clear toxic response, respectively (Lindon et al. 
2005). In addition, 21 physiological stressors, summa-
rised in Table  1, were studied to ascertain the metabolic 
effects of physiological processes that may compound 
those of the drugs and toxins administered. These treat-
ments included partial hepatectomy, unilateral nephrec-
tomy, chronic food or water restriction and administration 
of compounds that, for example, decrease renal tubular 
reabsorption (e.g. probenecid) (Silverman et al. 2008) or 
act as a carbonic anhydrase inhibitor (e.g. acetazolamide) 
(Molon-Noblot et al. 1992; Owen et al. 1993). The total 
number of studies carried out within the COMET project 
and the total number of studies for each target toxicity 
are presented in Supplementary Figure S1. Animals were 
acclimatised in standard cages (n = 5 animals per cage) 
for 2 weeks prior to the start of the experiment and sub-
sequently transferred to individual metabolism cages that 
were under regulated temperature and humidity conditions 
(21 ± 2 °C and 55 ± 10% respectively) in a fluorescently lit 
cycle of 12 “daily” hours (06:00 to 18:00) and 12 “nightly” 
hours. All rats were allowed unlimited amounts of food 
(Purina Chow 5002) and given free access to water across 
the entire study, except in studies designed to measure the 
impact of food or water restrictions. The full protocol is 
provided in the Supplementary Material.
Fig. 1  Schematic of the experimental design for the Consortium for Metabonomic Toxicology - COMET project
2672 Archives of Toxicology (2025) 99:2669–2681
Table 1  List of toxin names with corresponding dose routes, vehicles, dosages and target organ of toxicity
Toxin Dose route Dose vehicle Low dose High dose Affected organ
E 1,1-Dichloroethylene P.O Corn oil 37.5 mg/kg 150 mg/kg Liver
E 1,2,3,4,5,6-Hexachlorocy-
clohexane
I.P Corn oil 24 mg/kg 120 mg/kg Liver
B 1-Fluoropentane I.P 0.9% saline 2 mg/kg 20 mg/kg Liver
B 2,4,6-Trihydroxyacetophe-
none (THA)
I.P 2% DMSO in corn oil 40 mg/kg 400 mg/kg Liver
B 4-Amino-2,6-dichlorophe-
nol (ADCP)
I.P 2% DMSO in corn oil 7 mg/kg 70 mg/kg Liver
C Aflatoxin P.O 1% carboxymethyl 
cellulose
0.2 mg/kg 2 mg/kg Liver
C Allyl alcohol P.O 0.9% saline 12 mg/kg 120 mg/kg Liver
C Allyl formate I.P 0.9% saline 25 mg/kg 50 mg/kg Liver
B Azathioprine P.O 10% acacia + 0.1% 
antifoam
30 mg/kg 300 mg/kg Liver
B Bromobenzene P.O Corn oil 150 mg/kg 1500 mg/kg Liver
C Butylated hydroxytoluene P.O Corn oil 100 mg/kg 1000 mg/kg Liver
D Carbon tetrachloride P.O Corn oil 640 mg/kg 3200 mg/kg Liver
C Chlorpromazine I.P 0.9% saline 30 mg/kg 60 mg/kg Liver
B Clofibrate P.O 0.25% methyl cel-
lulose
100 mg/kg 1000 mg/kg Liver
B Cyproterone acetate I.P Corn oil 40 mg/kg 400 mg/kg Liver
A D-Galactosamine I.P 0.9% saline 50 mg/kg 500 mg/kg Liver
B Diethylhexylphthalate 
(DEHP)
P.O Distilled water 2000 mg/kg 20,000 mg/kg Liver
C Dimethylformamide 
(DMF)
I.P 0.9% saline 250 mg/kg 1000 mg/kg Liver
C Dimethylnitrosamine 
(DMN)
P.O Sterile water 1.5 mg/kg 15 mg/kg Liver
A Gadolinium chloride I.V 0.9% saline 1 mg/kg 10 mg/kg Liver
A, B, C, D, E, F Hydrazine P.O 0.9% saline 30 mg/kg 90 mg/kg Liver
E Indomethacin P.O 0.2% carboxymethyl 
cellulose
5 mg/kg 25 mg/kg Liver
E Ketoconazole P.O 0.9% saline 50 mg/kg 350 mg/kg Liver
C Lead acetate I.P Sterile water 11.4 mg/kg 114 mg/kg Liver
A Lipopolysaccharide (LPS) I.V 0.9% saline 0.5 mg/kg 5 mg/kg Liver
B Methapyrilene P.O Distilled water 20 mg/kg 200 mg/kg Liver
E Methylene dianiline P.O Corn oil 13 mg/kg 50 mg/kg Liver
C Monocrotaline P.O Sterile water 80 mg/kg 160 mg/kg Liver
C N-methylformamide 
(NMF)
I.P 0.9% saline 400 mg/kg 1000 mg/kg Liver
D Phalloidin (chronic) I.P 0.9% saline 0.25 mg/kg 0.75 mg/kg Liver
E Phenyl diisothiocyanate I.P Corn oil 2.25 mg/kg 11 mg/kg Liver
E Phenyl isothiocyanate I.P Corn oil 20 mg/kg 100 mg/kg Liver
B Retinyl palmitate P.O 10% acacia + 0.1% 
antifoam
50 mg/kg 500 mg/kg Liver
B Sodium valproate P.O Distilled water 200 mg/kg 2000 mg/kg Liver
C α-Naphthylisothiocyanate 
(ANIT)
P.O Corn oil 12.5 mg/kg 125 mg/kg Liver
D 2-Bromophenol I.P Corn oil 100 mg/kg 200 mg/kg Kidney
E 3,5-Dichloroaniline 
hydrochloride
I.P 0.9% saline 30 mg/kg 120 mg/kg Kidney
E Atractyloside I.P 0.9% saline 10 mg/kg 100 mg/kg Kidney
2673Archives of Toxicology (2025) 99:2669–2681 
Table 1  (continued)
Toxin Dose route Dose vehicle Low dose High dose Affected organ
D Bromoethylamine hydro-
bromide
I.P 0.9% saline 15 mg/kg 150 mg/kg Kidney
D Cephaloridine I.P 0.9% saline 200 mg/kg 900 mg/kg Kidney
B Chlorethanamine I.P 0.9% saline 100 mg/kg 1000 mg/kg Kidney
A Cisplatin I.P 0.9% saline 1 mg/kg 5 mg/kg Kidney
A D-Limonene (chronic) P.O Corn oil 15 mg/kg 150 mg/kg Kidney
E Dichlorophenyl succin-
imide
P.O Corn oil 43 mg/kg 170 mg/kg Kidney
D Ethylene glycol P.O 0.9% saline 0.5 mL/kg 3.0 mL/kg Kidney
A Folic acid I.P 150 mmol/L sodium 
bicarbonate solution
35 mg/kg 350 mg/kg Kidney
A Gentamicin P.O 0.9% saline 50 mg/kg 150 mg/kg Kidney
B Maleic acid P.O Distilled water 40 mg/kg 400 mg/kg Kidney
A N-phenylanthranilic acid 
(chronic)
P.O 0.5% aqueous methyl 
cellulose
65 mg/kg 650 mg/kg Kidney
D Para-aminophenol I.P 0.9% saline 40 mg/kg 150 mg/kg Kidney
A Puromycin I.P 0.9% saline 5 mg/kg 150 mg/kg Kidney
B Vancomycin hydrochlo-
ride
I.V 0.9% saline 20 mg/kg 200 mg/kg Kidney
E Acetaminophen P.O 0.2% carboxymethyl 
cellulose
400 mg/kg 1600 mg/kg Liver & Kidney
B Aurothiomalate I.P 0.9% saline 10 mg/kg 100 mg/kg Liver & Kidney
C Chloroform P.O Corn oil 50 mg/kg 500 mg/kg Liver & Kidney
D Cyclosporin P.O Corn oil 70 mg/kg 700 mg/kg Liver & Kidney
D Dichlorobenzene P.O Corn oil 75 mg/kg 400 mg/kg Liver & Kidney
C Ethionine P.O Methyl cellulose 200 mg/kg 800 mg/kg Liver & Kidney
B Hexachlorobutadiene 
(HCBD)
P.O Corn oil 20 mg/kg 200 mg/kg Liver & Kidney
B Mercuric chloride I.P 0.9% saline 0.5 mg/kg 2 mg/kg Liver & Kidney
E Microcystin-LR I.P 0.9% saline 0.02 mg/kg 0.08 mg/kg Liver & Kidney
E Rotenone P.O Corn oil 10 mg/kg 100 mg/kg Liver & Kidney
E S-(1,2-dichlorovinyl)-
cysteine (DCVC)
I.P 0.9% saline 6 mg/kg 60 mg/kg Liver & Kidney
D Thioacetamide I.P 0.9% saline 20 mg/kg 100 mg/kg Liver & Kidney
E 1-Cyano-2-hydroxy-
3-butene
I.P 0.9% saline 15 150 Pancreas
C Caerulein I.P 0.05 M sodium 
hydroxide in 0.9% 
saline
0.05 mg/kg 0.2 mg/kg Pancreas
E L-arginine I.P 0.9% saline 1000 mg/kg 4000 mg/kg Pancreas
B Streptozotocin I.P 10 mM citrate buffer 25 mg/kg 60 mg/kg Pancreas
D 1,3-Dinitrobenzene P.O Corn oil 10 mg/kg 30 mg/kg Testicular
C Cadmium chloride P.O Sterile water 7.5 mg/kg 75 mg/kg Testicular
D Cadmium chloride I.P 0.9% saline 0.75 mg/kg 1.5 mg/kg Testicular
D Carbendazim P.O Corn oil 50 mg/kg 400 mg/kg Testicular
D Di-n-pentyl-phthalate P.O Corn oil 1100 mg/kg 2200 mg/kg Testicular
D Ethane dimethane sulpho-
nate (EDS)
I.P DMSO:water (1:3) 30 mg/kg 100 mg/kg Testicular
D Methoxyacetic acid P.O 0.9% saline 150 mg/kg 650 mg/kg Testicular
B Adriamycin I.V 0.9% saline 2 mg/kg 10 mg/kg Multiple organ
C Amphotericin B I.P Sterile water 5 mg/kg 50 mg/kg Multiple organ
C Azaserine I.P 0.9% saline 8 mg/kg 80 mg/kg Multiple organ
2674 Archives of Toxicology (2025) 99:2669–2681
Sample collection
Urine samples were collected across an 8-day period includ-
ing both day and night time points. All animals were placed 
in metabolism cages 48 h prior to the first urine collection 
to allow the animals to acclimatise. Urine samples were col-
lected at 16 h pre-dose covering the continuous collection 
over the 8 h period from −24 h to −16, then 0 (−16–0 h 
pre-dose), 8 (0–8 h post-dose), 24 (8–24 h post-dose), 48 
(24–48 h post-dose), 72 (48–72 h post-dose), 96 (72–96 h 
Table 1  (continued)
Toxin Dose route Dose vehicle Low dose High dose Affected organ
A Dexamethasone I.P 10% DMSO in corn 
oil
2 mg/kg 100 mg/kg Multiple organ
E Mitomycin-C I.P 0.9% saline 1 4 Multiple organ
C 1,1-Dichloroethylene and 
maleic acid
P.O Corn oil/sterile water 40 mg 1,1-dichloro-
ethylene/kg in corn 
oil
200 mg maleic acid/
kg in sterile water
Physiological stressor
C 2,4-Dinitrophenol P.O Water 1.5 mg/kg 15 mg/kg Physiological stressor
B 4-Pentenoic acid P.O Corn oil 50 mg/kg 350 mg/kg Physiological stressor
D Acetazolamide P.O 0.5% methyl cellulose 60 mg/kg 600 mg/kg Physiological stressor
C Acivicin I.P 0.9% saline 1 mg/kg 10 mg/kg Physiological stressor
E Ammonium chloride P.O 0.9% saline 0 0.02 Physiological stressor
D Carboplatin I.V 0.9% saline 30 mg/kg 60 mg/kg Physiological stressor
A Choline and choline/
methionine deficiency 
(chronic)
Diet modification Choline devoid (CD) 
diet
Choline + methionine 
devoid (CMD) diet
Physiological stressor
B Food restriction (chronic) Diet modification 75% of the regular 
food intake
0% of the regular food 
intake for 24 h
Physiological stressor
D Furosemide P.O 0.9% saline 10 mg/kg 50 mg/kg Physiological stressor
B Insulin S.C 0.9% saline 10 IU/kg 750 IU/kg Physiological stressor
E Methotrexate P.O 0.2% carboxymethyl 
cellulose
40 mg/kg 400 mg/kg Physiological stressor
A Partial hepatectomy Surgical study Sham surgery (SS) Partial hepatectomy 
(PH)
Physiological stressor
A Phenobarbital (chronic) I.P 0.9% saline 10 mg/kg 100 mg/kg Physiological stressor
A Pregnenolone 16 alpha 
carbonitrile (chronic)
P.O Carboxymethyl cel-
lulose
10 mg/kg 100 mg/kg Physiological stressor
A Probenecid I.P 0.9% saline 20 mg/kg 200 mg/kg Physiological stressor
C Rosiglitazone P.O 1% methyl cellulose 100 mg/kg 500 mg/kg Physiological stressor
C Rosiglitazone (chronic) P.O 1% methyl cellulose 10 mg/kg 100 mg/kg Physiological stressor
E Sodium bicarbonate P.O Drinking water 0.1 M 0.35 M Physiological stressor
A Unilateral nephrectomy Surgical study Sham surgery (SS) Unilateral nephrec-
tomy (UN)
Physiological stressor
B Water deprivation 
(chronic)
Diet modification Deprived for 24 h Deprived for 48 h Physiological stressor
E Acetaminophen (chronic) P.O 0.2% carboxymethyl 
cellulose
200 mg/kg 800 mg/kg No Effect
C Buthionine sulphoxime I.P 0.9% saline 222 mg/kg 889 mg/kg No Effect
C Ferrous sulphate P.O Distilled water 250 mg/kg 1250 mg/kg No Effect
B Ifosfamide P.O 10% acacia + 0.1% 
antifoam
10 mg/kg 100 mg/kg No Effect
B Lithocholic acid P.O 10% acacia + 0.1% 
antifoam
10 mg/kg 100 mg/kg No Effect
E Paraquat I.P 0.9% saline 5 mg/kg 22.5 mg/kg No Effect
D Potassium dichromate I.P 0.9% saline 10 mg/kg 20 mg/kg No Effect
C Trichlorethylene I.P Corn oil 200 mg/kg 1000 mg/kg No Effect
A-F: indicates pharmaceutical company and sample origin
2675Archives of Toxicology (2025) 99:2669–2681 
post-dose), 120 (96–120 h post-dose), 144 (120–144 h post-
dose) and 168 (144–168 h post-dose) as described in Fig. 1. 
Serum samples were collected from all rats via tail vein 
puncture 24 h after dosing. Half the rats from each group 
were euthanised at 48 h post-dose and the other half at 168 h 
post-dose to assess both the acute and chronic effects of 
each toxin. Serum and tissue samples were collected upon 
euthanisation, and histopathological examination was con-
ducted. Serum samples were split into two aliquots, one 
for in-house clinical chemistry analysis and one for pro -
ton nuclear magnetic resonance ( 1H NMR) spectroscopic 
analysis (performed at Imperial College London). The urine 
samples were collected into containers with 1 mL of 1% w/v 
sodium azide as a bactericide and maintained at 0 ± 2 °C. On 
collection, the urine volume was recorded and approximately 
one-third of each urine sample was transferred to a tube for 
urinalysis and submitted to clinical pathology. The remain-
der of the sample was centrifuged for 10 min at ~ 1200 g and 
subsequently stored at a temperature of –40 °C until NMR 
analysis. Urinary volume was recorded, and osmolality was 
measured using a freezing point depression osmometer and 
all clinical assays were performed using standard in-house 
protocols.
Data curation and statistical analyses
Improbable values in the clinical chemistry data, for exam-
ple negative concentration values, were identified through 
basic univariate statistic and removed. Parameters with more 
than 40% data missing were also removed. A random forest 
(RF) imputation approach, using the missForest (R package 
v1.5), was applied to all missing clinical values (number and 
percentage of missing values for each parameter is provided 
in Supplementary Table S1) in the entire dataset (control, 
low-dose and high-dose samples). The performance of the 
imputation method was validated through comparing the 
distributions of the imputed dataset to the original dataset 
using half violin boxplots (Figure S2-S4) with accompa -
nying normalised root mean square error (NRMSE) values 
for each parameter. For the purpose of illustration, the dis-
tributions for the control, low-dose and high-dose samples 
are shown in Figures S2, S3 and S4. The distribution prior 
and post-imputation is shown in green and purple respec-
tively for each clinical parameter. The normalised root mean 
square error (NRMSE) values generated using the missFor-
est algorithm are also reported along with the percentage 
and number of missing values within each dose group. The 
distributions for both the original and imputed datasets are 
symmetrical across all parameters and dose groups, vali-
dating that the imputation process did not alter the overall 
distribution of the data.
Univariate statistics for each parameter were summa-
rised for all control samples (n  = 13,200). The median, 
minimum, maximum, mean and standard deviation values 
are provided in Supplementary Table S2. Additionally, simi-
lar values were computed for each individual toxin and for 
every parameter at 24 h, 48 h and 168 h post-dose vehi -
cle and post-high-dose administration and are provided in 
the Supplementary Material (Supplementary Table S3-S19 
post-dose vehicle; Supplementary Table S20-S36 post-high 
dose). To visualise the impact of the toxins on the clinical 
chemistry parameters, scatter plots were generated from all 
toxins using samples from 24 h post-dose. Correlation matri-
ces, based on the Spearman’s correlation coefficient, were 
generated for the control dataset and for subsets of the high-
dose administered data using samples from all time points 
and stratified by toxicity type: liver; kidney; liver and kid-
ney; pancreas and testes, to visualise the correlation between 
clinical chemistry parameters and to identify organ-specific 
toxicity profiles.
Results
An atlas in SQL format
The summary serum clinical chemistry values (median, min, 
max, mean, standard deviation) for control Sprague–Dawley 
rats for the COMET project at 24 h, 48 h and 168 h post-
injection with dosing vehicle are listed in Supplementary 
Tables S3-S19, stratified by main organ or tissue of toxicity 
and identified by the source of sample origin (pharmaceu-
tical company). Summary statistics for serum parameters 
are listed by assay: calcium (Supplementary Table S3), 
sodium (Supplementary Table S4), potassium (Supple-
mentary Table S5), phosphate (Supplementary Table S6), 
glucose (Supplementary Table S7), albumin (Supplemen-
tary Table S8), total protein (Supplementary Table S9), 
total bilirubin (Supplementary Table S10), urea nitrogen 
(Supplementary Table S11), creatinine (Supplementary 
Table S12), ALT (Supplementary Table S13) and AST (Sup-
plementary Table S14). Urine clinical chemistry parameters 
for matched time points to the serum samples are provided 
in Supplementary Tables S15-S19. Urine clinical chemistry 
summary statistics are provided for urinary volume (Supple-
mentary Table S15), pH (Supplementary Table S16), osmo-
lality (Supplementary Table S17), glucose (Supplementary 
Table S18) and protein (Supplementary Table S19). The 
corresponding summary clinical chemistry values for rats 
post-high-dose administration are listed in Supplementary 
2676 Archives of Toxicology (2025) 99:2669–2681
Tables S20-S36. The raw values, batch corrected values and 
batch corrected with imputed values for each sample are 
provided as open-source sqlite1 database file allowing read-
ers to readily explore the impact of dose vehicle, route and 
toxin on the panel of standard clinical assays, as well as 
to explore inter-animal variability. With 26,546 entries for 
3545 animals, this is the largest body of clinical chemistry 
data collected under a common protocol published for acute 
rodent toxicity studies and provides a benchmark for control 
value ranges in Sprague–Dawley rats.
Assessment of toxicological effect
Although the model compounds were selected based on lit-
erature reports of toxic effect, not all toxins, sometimes even 
at high dose, were found to induce reproducible histopatho-
logical consequences as indicated for animals euthanised 
at 48 h and 168 h. Treatments that failed to elicit a toxic 
response, as defined by histopathology are listed at the base 
of Table 1. For these compounds, none of the clinical chem-
istry measurements were significantly out of the control 
range. It should be noted that all studies were performed 
according to prevailing best laboratory practices in the pro-
fessional pharmaceutical laboratories and so the observed 
variation for some compounds reflects intrinsic biological 
variation rather than procedural.
For certain parameters, the baseline was noisy with a 
high degree of variation in measurement values apparent in 
the control groups as well as the dosed, making it difficult 
to conclusively attribute small changes in mean or median 
values to toxic effect. The relative impact of the model tox-
ins and clinical chemistry values at 24 h post-dose can be 
visualised in Fig. 2. Scatter plots for the parameters demon-
strated good reproducibility. Both the low- and high-dose 
groups for each toxin were denoted by black and red data 
points, respectively, and contrasted with the control samples 
depicted as grey data points. The data points were ordered 
consecutively by study, with control samples placed in a 
separate category on the left-hand side of the scatter plot 
for ease of visualisation. The treated samples were ordered 
Fig. 2  Scatter plots of clinical chemistry parameters using samples 
taken 24  h post-dose. Control, low-dose and high-dose groups are 
represented as grey, black and red points, respectively. Background 
colour corresponds to the target organ of toxicity: control (grey), 
kidney (orange), liver (dark green), liver and kidney (pink), pancreas 
(purple) and testes (light green). Abbreviations: aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT)
1 Sqlite databases can be shared as a regular file, i.e., without the 
requirement to install and configure a database server. It is an indus-
try grade open-source format that allows to perform queries in SQL 
language and that will work on any operating system.
2677Archives of Toxicology (2025) 99:2669–2681 
by primary organ of toxicity, indicated by the shaded back-
ground: control (grey), kidney (orange), liver (dark green), 
liver and kidney (pink), pancreas (purple) and testes (light 
green). As expected, this stratification of the data by organ 
of toxicity shows ‘spikes’ in the overall distribution of data 
points for a given parameter. In addition, toxins that targeted 
the same organ showed expected similarities in their clini-
cal chemical profiles, although not all toxins targeting the 
same organ demonstrated equivalent profiles due to differ -
ences in the extent of the pathological lesions and differ -
ences in the time of response of individuals. For example, 
two distinct spikes in the total serum bilirubin plot (Fig. 2b) 
are associated with the high dose for d-galactosamine and 
α-naphthylisothiocyanate (ANIT), both being potent liver 
toxins. Similarly for urinary glucose (Fig. 2i), the ‘spike’ is 
in the pancreatic band and associated with streptozotocin. 
Also, there is a large dynamic range of response in some 
of the parameters, for example aspartate aminotransferase 
(AST).
Correlation between parameters enhances 
the predictivity of the toxicity type
To obtain a more generalised overview of response across 
the different toxicity types, correlation matrices (Fig.  3) 
between the clinical chemistry parameters using samples 
from all time points were constructed. For control animals 
(Fig. 3a), a strong inter-parameter correlation was evident 
between total serum protein and serum albumin (r  = 0.74), 
while weaker correlations were observed between urine glu-
cose and osmolality (r = 0.59), serum calcium and phosphate 
(r = 0.52) and urine protein and osmolality (r = 0.49). Urine 
glucose and osmolality were weakly anti-correlated with 
urine pH in the control dataset ( r = −0.34 urine glucose to 
pH; r = −0.33 osmolality to pH). In the case of liver toxic-
ity (Fig.  3b), AST, ALT and bilirubin were all correlated 
with each other (r = 0.82 AST to ALT; r = 0.41 AST to bili-
rubin, r = 0.38 ALT to bilirubin) and negatively correlated 
with serum glucose (r  = −0.38 AST to glucose; r = −0.29 
ALT to glucose; r  = −0.2 bilirubin to glucose). The cor -
relation between total serum protein and serum albumin 
Fig. 3  Spearman’s correlations between clinical chemistry parameters 
using all time points for control samples (a), and high-dose samples 
that were administered. Liver-targeting toxin (b), kidney-targeting 
toxin (c), liver and kidney-targeting toxin (d), pancreas-targeting 
toxin (e) and testicular-targeting toxin (f)
2678 Archives of Toxicology (2025) 99:2669–2681
observed for the control dataset was retained, but not the 
anti-correlation between urine pH and osmolality. Instead, 
a weak anti-correlation was noted between urine glucose 
and pH (r = −0.27). The correlation matrix for renal toxicity 
(Fig. 3c) showed a different inherent pattern from control or 
from hepatotoxicity. Here, the strongest correlations were 
between total serum protein and serum albumin (r = 0.77) 
and between urea nitrogen and serum creatinine (r  = 0.59). 
As observed for hepatotoxins, an inverse association was 
apparent between urine volume and osmolality (r = −0.40). 
As expected, the correlations for toxins targeting the liver 
and kidney (Fig. 3d) showed characteristics of both the indi-
vidual correlation matrices for liver and kidney toxins. For 
pancreatic toxins (Fig.  3e), the strongest correlation was 
between total serum protein and albumin (r  = 0.91), and 
AST and ALT (r  = 0.75). For testicular toxicity (Fig.  3f), 
the defining features were direct correlations between serum 
ions calcium, potassium and phosphate (r  = 0.70 potassium 
to phosphate, r  = 0.64 potassium to calcium; r  = 0.60 cal-
cium to phosphate), and correlations between urine glucose 
and urine protein (r  = 0.67), and serum calcium and serum 
sodium (r = 0.65). As for hepatotoxins, a strong association 
between total serum protein and albumin (r  = 0.73) was 
observed.
Discussion
We present a summary of clinical chemistry data for one of 
the largest academic acute toxicology projects yet commis-
sioned as a reference database for Sprague-Dawley rats. We 
summarise the statistics for control Sprague–Dawley rats 
(n = 3473) as well as 35 liver toxins, 17 kidney toxins, 12 
toxins targeting both liver and kidney, 4 pancreatic toxins, 
6 testicular toxins and 5 toxins targeting multiple organs. 
In addition, we present data for 21 surgical and physiologi-
cal stressors to allow for the characterisation of specific 
metabolic responses that may be part of, or may confound 
the predominant toxicological response. All studies were 
carefully planned so that all treatments were under the most 
similar conditions possible, including food sources and all 
sampling regimes. We also provide data for eight treatments 
that elicited no demonstrable effect, as ascertained by histo-
pathology and clinical chemistry. All raw and curated data 
are provided as an SQL database (before and after batch 
correction and imputation) to facilitate researchers to reuse 
and integrate the data into their own models and databases.
Based on data acquired at 24 h post-dose, we show organ-
specific patterns in clinical chemistry parameters using both 
univariate and correlation analyses. As expected, there is a 
range of magnitudes in the response to toxins, even within 
a set of organ-specific toxins. For example, elevated serum 
concentrations of AST and ALT, together with bilirubin, 
are classically associated with liver toxicity, but the range 
associated with each liver toxin is different such that some 
toxins are associated with values that reflect between a 
0.5- and 28-fold increase in serum bilirubin. For example, 
α-naphthylisothiocyanate and D-galactosamine demonstrate 
a response that is an order of magnitude greater than other 
liver toxins (Fig. 2b). The differences in magnitude relate to 
the extent of damage, the time of collection and the sub-tis-
sue and/or mechanism of pathology. Some parameters show 
contrasting behaviour in response to toxins targeting a par -
ticular organ. For example, whereas most liver toxins elicit 
an increase in liver enzymes AST and ALT, the steatotic 
liver toxin hydrazine is a transaminase inhibitor, and in this 
case causes a decrease in the concentration of these enzymes 
compared to the mean values for control animals as previ -
ously noted (Garrod 2005).
One of the disadvantages of relying on clinical chem-
istry parameters as measures of toxic response, is the fact 
that many serum and/or urinary clinical markers are tran -
sitory following a single dose alone of a toxic compound. 
This is particularly true for enzymes such as AST and ALT, 
whereby it is feasible that a peak in enzyme release from 
the cells into the bloodstream may be missed as enzymes 
tend to be present in short bursts (Nicholson et al. 2002; 
Ramaiah 2007). As toxicity profiles were generated for 24, 
48 and 168 h (serum samples), and only the 24 h post dose 
samples were modelled here for illustrative purposes, it is 
almost certain that the exposure window was not optimal for 
most compounds.
The power of considering multivariate relationships 
between clinical parameters, thereby capturing interactions 
between parameters, is illustrated by the correlation plots in 
Fig. 3 and could be further extended to multivariate model-
ling. For example, an increase in urine glucose is a key fea-
ture of both kidney and pancreatic toxicity, but only for pan-
creatic toxicity is this accompanied by elevations in serum 
glucose and reflects the osmotic ‘drag’ created by the high 
concentration of glucose in the renal tubules which causes 
diffusion of water into the tubules to maintain osmotic bal-
ance. Organs are not typically homogeneous in structure and 
multiple studies have described variation in clinical chem-
istry parameters according to the site of toxicity within an 
organ. For example, necrosis of the renal papilla is more 
likely to induce vast increases in urine volume and decreases 
in osmolality compared to a toxin that targets the renal 
cortex, whereas a toxin that induces necrosis in the renal 
proximal convoluted tubule will manifest as an inability to 
reabsorb glucose, electrolytes and other compounds result-
ing in an increase of these species in urine (Radi 2019). 
Similarly, the mechanism of action of a toxin can result in 
differences in the clinical chemistry signature. An obvi-
ous example would be a hepatotoxin such as hydrazine that 
inhibits transaminases compared to a cholestatic hepatotoxin 
2679Archives of Toxicology (2025) 99:2669–2681 
such as galactosamine that causes release of transaminases 
into the blood. Those data provided here are derived from 
toxins targeting a range of sites (e.g. glomerulus, cortex and 
papilla within the kidney) and a range of mechanisms (e.g. 
cholestasis, steatosis, necrosis) allowing readers to select 
appropriate benchmarks as comparators for their own stud-
ies. Indeed, the characterisation of a particular compound 
as a “liver toxin” or “kidney toxin” is overly simplistic as 
highlighted in this compendium of data.
Finally, the provision of a large body of clinical chemistry 
data for control Sprague–Dawley rats shows stratification 
according to pharmaceutical company and study. These 
observed inter-laboratory differences are most likely a 
product of minor differences in laboratory environment 
and although the study protocol extended to details such 
as batch of chow diet, the source of the animals and their 
exposure to environmental differences prior to the study 
may account for some of these differences (Ericsson and 
Franklin 2021; Robosky et al. 2005). The ranges we report 
here largely match the values reported in the literature. In the 
case of serum sodium, calcium and albumin (Supplementary 
Table 2), the values reported substantially overlap with 
those reported by Petterino and Argentino-Storino (2006). 
However, for some parameters, there are significant 
differences between those reported in the literature for 
Sprague–Dawley rats. Serum urea nitrogen (umol/L) and 
total bilirubin (umol/L) are two such examples where we 
find a range of 1430–16000 with a median, mean and 
standard deviation of 5000, 5237 and 1143, respectively, for 
urea nitrogen and a range of 0–34.34 with a median, mean 
and standard deviation of 1.2, 1.42 and 1.1, respectively, 
for total bilirubin. As we provide the raw measurement 
values in addition to batch-corrected and imputed data, it is 
possible for us to estimate what percentage of ‘spurious’ or 
improbable values would be expected in a large study and to 
provide a baseline for improving power calculations. 
Conclusion
We provide an atlas of toxic effects of a wide range of drugs 
and model toxins with different sites and mechanisms of 
toxicity. To our knowledge, this is the largest collated set of 
clinical chemistry parameters published for rodent toxicity 
models and should help provide a resource for benchmarking 
acute toxicity studies in rat models. Tables with basic 
statistics (median, range, mean and standard deviation) 
for controls and high-dosed samples are available in the 
Supplementary Information. The raw values, values after 
outlier removal, values after batch correction and values 
after imputation are provided as sqlite tables (See Data 
Availability).
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00204- 025- 04008-0.
Acknowledgements We thank the pharmaceutical companies (Phar -
macia, Pfizer, Hoffman-La Roche, Bristol Myers Squibb, Eli Lilly and 
Co., and Novo Nordisk) and all members of the COMET project for 
financial support for the COMET project and access to data.
Author contributions Conceptualisation: Jeremy Nicholson, Elaine 
Holmes, John Lindon, Protocol development: Michael Reily, Don-
ald Robertson, Lois Lehman-McKeeman, John Shockcor, Bruce Car, 
Glenn Cantor, Jake Pearce, John Lindon, Jeremy Nicholson, Elaine 
Holmes. Formal analysis: Janonna Kadyrov, Samuele Sala, Lucy 
Grigoroff, Novia Minaee, Reika Masuda, Samantha Lodge, Timothy 
Ebbels, Jake Pearce, Jeremy Nicholson, Elaine Holmes, Julien Wist. 
Writing—original draft preparation: Janonna Kadyrov, Samuele Sala, 
Elaine Holmes, Julien Wist, Jeremy Nicholson. Writing—reviewing 
and editing: all authors reviewed and edited the final draft. Visualisa-
tion: Janonna Kadyrov, Lucy Grigoroff, Elaine Holmes, Julien Wist. 
Resources: Jeremy Nicholson, Elaine Holmes. Data curation: Janonna 
Kadyrov, Lucy Grigoroff, Novia Minaee, Reika Masuda, Julien Wist. 
Supervision: Elaine Holmes, Julien Wist, Jeremy Nicholson, John 
Lindon. Project administration: Elaine Holmes, Julien Wist, Jeremy 
Nicholson. Funding acquisition: Jeremy Nicholson, Elaine Holmes, 
John Lindon. All authors have reviewed and approved the published 
version of the manuscript.
Funding Open Access funding enabled and organized by CAUL and 
its Member Institutions. We thank the Commonwealth of Australia for 
funding author J.K. through a Research Training Program Scholarship. 
We thank the Department of Jobs, Tourism, Science and Innovation, 
Government of Western Australian Premier’s Fellowship and the ARC 
Laureate Fellowship for funding author E.H. and the Medical Research 
Future Fund for funding the Australian National Phenome Centre. We 
thank the pharmaceutical companies Pharmacia, Pfizer, Hoffman-La 
Roche, Bristol Myers Squibb, Eli Lilly and Co. and Novo Nordisk for 
financial support of the COMET project.
Data availability The datasets generated during and/or analysed during 
the current study are available in the zenodo.org repository, https:// doi. 
org/ 10. 5281/ zenodo. 14963 725.
Declarations 
Conflict of interest The authors declare no conflicts of interest.
Ethical approval All animal studies were conducted in accordance with 
the current guidelines for animal welfare (Guide for the Care and Use 
of Laboratory Animals, 1996) and the procedures used were reviewed 
and approved by the Institutional Animal Care and Use Committee in 
each company.
Consent to participate Not applicable.
Consent for publication All authors reviewed and approved the final 
manuscript.
Open Access This article is licensed under a Creative Commons 
Attribution 4.0 International License, which permits use, sharing, 
2680 Archives of Toxicology (2025) 99:2669–2681
adaptation, distribution and reproduction in any medium or format, 
as long as you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons licence, and indicate 
if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless 
indicated otherwise in a credit line to the material. If material is not 
included in the article’s Creative Commons licence and your intended 
use is not permitted by statutory regulation or exceeds the permitted 
use, you will need to obtain permission directly from the copyright 
holder. To view a copy of this licence, visit http://creativecommons.
org/licenses/by/4.0/.
References
Amorim AMB, Piochi LF, Gaspar AT, Preto AJ, Rosário-Ferreira N, 
Moreira IS (2024) Advancing drug safety in drug development: 
bridging computational predictions for enhanced toxicity predic-
tion. Chem Res Toxicol 37(6):827–849. https:// doi. org/ 10. 1021/ 
acs. chemr estox. 3c003 52
Araújo AM, Carvalho F, Guedes de Pinho P, Carvalho M (2021) Toxi-
cometabolomics: small molecules to answer big toxicological 
questions. Metabolites 11(10):692–722. https:// doi. org/ 10. 3390/ 
metab o1110 0692
Bohus E, Coen M, Keun HC, Ebbels TM, Beckonert O, Lindon JC, 
Holmes E, Noszál B, Nicholson JK (2008) Temporal meta-
bonomic modeling of l-arginine-induced exocrine pancreatitis. 
J Proteome Res 7(10):4435–4445. https:// doi. org/ 10. 1021/ pr800 
407j
Bollard ME, Contel NR, Ebbels TM, Smith L, Beckonert O, Cantor 
GH, Lehman-McKeeman L, Holmes EC, Lindon JC, Nicholson 
JK, Keun HC (2010) NMR-based metabolic profiling identifies 
biomarkers of liver regeneration following partial hepatectomy 
in the rat. J Proteome Res 9(1):59–69. https:// doi. org/ 10. 1021/ 
pr900 200v
Cantor GH, Beckonert O, Bollard ME, Keun HC, Ebbels TM, Antti 
H, Wijsman JA, Bible RH, Breau AP, Cockerell GL, Holmes E, 
Lindon JC, Nicholson JK (2013) Integrated histopathological 
and urinary metabonomic investigation of the pathogenesis of 
microcystin-LR toxicosis. Vet Pathol 50(1):159–171. https:// doi. 
org/ 10. 1177/ 03009 85812 443839
Ebbels TMD, Keun HC, Beckonert OP, Bollard ME, Lindon JC, Hol-
mes E, Nicholson JK (2007) Prediction and classification of drug 
toxicity using probabilistic modeling of temporal metabolic data: 
the consortium on metabonomic toxicology screening approach. 
J Proteome Res 6(11):4407–4422. https:// doi. org/ 10. 1021/ pr070 
3021
Ericsson AC, Franklin CL (2021) The gut microbiome of labora-
tory mice: considerations and best practices for translational 
research. Mamm Genome 32(4):239–250. https:// doi. org/ 10. 1007/ 
s00335- 021- 09863-7
Garrod S, Bollard ME, Nicholls AW, Connor SC, Connelly J, Nichol-
son JK, Holmes E (2005) Integrated metabonomic analysis of 
the multiorgan effects of hydrazine toxicity in the rat. Chem Res 
Toxicol 18(2):115–122
Lindon JC, Nicholson JK, Holmes E, Antti H, Bollard ME, Keun H, 
Beckonert O, Ebbels TM, Reily MD, Robertson D, Stevens GJ, 
Luke P, Breau AP, Cantor GH, Bible RH, Niederhauser U, Senn 
H, Schlotterbeck G, Sidelmann UG, Laursen SM, Tymiak A, 
Car BD, Lehman-McKeeman L, Colet JM, Loukaci A, Thomas 
C (2003) Contemporary issues in toxicology the role of meta-
bonomics in toxicology and its evaluation by the COMET project. 
Toxicol Appl Pharmacol 187(3):137–146. https:// doi. org/ 10. 1016/ 
s0041- 008x(02) 00079-0
Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes E, Nicholson JK 
(2005) The Consortium for Metabonomic Toxicology (COMET): 
aims, activities and achievements. Pharmacogenomics 6(7):691–
699. https:// doi. org/ 10. 2217/ 14622 416.6. 7. 691
Molon-Noblot S, Boussiquet-Leroux C, Owen RA, Irisarri E, Durand-
Cavagna G, Peter CP, Duprat P (1992) Rat urinary bladder hyper-
plasia induced by oral administration of carbonic anhydrase inhib-
itors. Toxicol Pathol 20(1):93–102. https:// doi. org/ 10. 1177/ 01926 
23392 02000 111
Nicholson JK et al (1989) Quantitative high resolution 1H NMR uri-
nalysis studies on the biochemical effects of cadmium in the rat. 
Mol Pharmacol 36(3):398–404
Nicholson et al (2002). https:// doi. org/ 10. 1038/ nrd728
Olesti E, González-Ruiz V, Wilks MF, Boccard J, Rudaz S (2021) 
Approaches in metabolomics for regulatory toxicology applica-
tions. Analyst 146(6):1820–1834. https:// doi. org/ 10. 1039/ D0AN0 
2212H
Owen RA, Durand-Cavagna G, Molon-Noblot S, Boussiquet-Leroux C, 
Berry PH, Tonkonoh N, Peter CP, Gordon LR (1993) Renal papil-
lary cytoplasmic granularity and potassium depletion induced by 
carbonic anhydrase inhibitors in rats. Toxicol Pathol 21(5):449–
455. https:// doi. org/ 10. 1177/ 01926 23393 02100 504
Radi ZA (2019) Kidney pathophysiology, toxicology, and drug-induced 
injury in drug development. Int J Toxicol 38(3):215–227. https:// 
doi. org/ 10. 1177/ 10915 81819 831701
Ramaiah SK (2007) A toxicologist guide to the diagnostic interpre-
tation of hepatic biochemical parameters. Food Chem Toxicol 
45(9):1551–1557. https:// doi. org/ 10. 1016/j. fct. 2007. 06. 007
Robertson DG (2005) Metabonomics in toxicology: a review. Toxicol 
Sci 85(2):809–822. https:// doi. org/ 10. 1093/ toxsci/ kfi102
Robertson DG, Watkins PB, Reily MD (2011) Metabolomics in 
toxicology: preclinical and clinical applications. Toxicol Sci 
120(S1):S146–S170. https:// doi. org/ 10. 1093/ toxsci/ kfq358
Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Rob-
ertson DG (2005) Metabonomic identification of two distinct 
phenotypes in Sprague-Dawley (Crl:CD(SD)) rats. Toxicol Sci 
87(1):277–284. https:// doi. org/ 10. 1093/ toxsci/ kfi214
Sanins et al (1992). https:// doi. org/ 10. 1007/ BF019 70674
Shockcor JP, Holmes E (2002) Metabonomic applications in toxicity 
screening and disease diagnosis. Curr Top Med Chem 2(1):35–51. 
https:// doi. org/ 10. 2174/ 15680 26023 394498
Silverman W, Locovei S, Dahl G (2008) Probenecid, a gout rem-
edy, inhibits pannexin 1 channels. Am J Physiol Cell Physiol 
295(3):C761–C767. https:// doi. org/ 10. 1152/ ajpce ll. 00227. 2008
Smith JR, Bolton ER, Dwinell MR (2019) The Rat: A Model Used in 
Biomedical Research. In: Hayman G, Smith J, Dwinell M, Shi -
moyama M (eds) Rat Genomics. Methods in molecular biology, 
vol 2018. Humana, New York, pp 1–41
Stark C, Steger-Hartmann T (2015) Nonclinical Safety and Toxicology. 
In: Nielsch U, Fuhrmann U, Jaroch S (eds) New Approaches to 
Drug Discovery, vol 232. Springer, Cham, pp 261–283
Tosca EM, Bartolucci R, Magni P, Poggesi I (2021) Modeling 
approaches for reducing safety-related attrition in drug discovery 
and development: a review on myelotoxicity, immunotoxicity, 
cardiovascular toxicity, and liver toxicity. Expert Opin Drug Dis-
cov 16(11):1365–1390. https:// doi. org/ 10. 1080/ 17460 441. 2021. 
19311 14
2681Archives of Toxicology (2025) 99:2669–2681 
Tran TTV, Wibowo AS, Tayara H, Chong KT (2023) Artificial intelli-
gence in drug toxicity prediction: recent advances, challenges, and 
future perspectives. J Chem Inf Model 63(9):2628–2643. https://  
doi. org/ 10. 1021/ acs. jcim. 3c002 00
Veselkov KA, Pahomov VI, Lindon JC, Volynkin VS, Crockford D, 
Osipenko GS, Davies DB, Barton RH, Bang JW, Holmes E, 
Nicholson JK (2010) A metabolic entropy approach for measure-
ments of systemic metabolic disruptions in patho-physiological 
States. J Proteome Res 9(7):3537–3544. https:// doi. org/ 10. 1021/ 
pr100 0576
Walker PA, Ryder S, Lavado A, Dilworth C, Riley RJ (2020) The evo-
lution of strategies to minimise the risk of human drug-induced 
liver injury (DILI) in drug discovery and development. Arch Toxi-
col 94:2559–2585. https:// doi. org/ 10. 1007/ s00204- 020- 02763-w
Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, 
Giacomini KM, Krauss RM (2007) Identifying genetic risk fac-
tors for serious adverse drug reactions: current progress and chal-
lenges. Nat Rev Drug Discov 6(11):904–916. https:// doi. org/ 10. 
1038/ nrd24 23
Publisher's Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.